Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Jtk 303

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,056Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 10Genvoya

    02 5Prezista/Prezcobix/Rezolsta/Symtuza

    03 2Revenue share - Symtuza

    04 10Stribild

    05 3Symtuza

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Symtuza

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ICMD China
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    ICMD China
    Not Confirmed

    Gilead

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 488

    2019 Revenue in Millions : 379

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ICMD China
    Not Confirmed

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    U.S.A
    arrow
    ICMD China
    Not Confirmed

    Johnson & Johnson

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 2,184

    2019 Revenue in Millions : 2,110

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Genvoya

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ICMD China
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    ICMD China
    Not Confirmed

    Gilead

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 3,338

    2019 Revenue in Millions : 3,931

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Stribild

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ICMD China
    Not Confirmed

    Brand Name : Stribild

    U.S.A
    arrow
    ICMD China
    Not Confirmed

    Gilead

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 196

    2019 Revenue in Millions : 369

    Growth (%) : -47

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Symtuza

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ICMD China
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    ICMD China
    Not Confirmed

    Gilead

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 531

    2020 Revenue in Millions : 488

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Genvoya

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ICMD China
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    ICMD China
    Not Confirmed

    Gilead

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 2,879

    2020 Revenue in Millions : 3,338

    Growth (%) : -14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Stribild

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ICMD China
    Not Confirmed

    Brand Name : Stribild

    U.S.A
    arrow
    ICMD China
    Not Confirmed

    Gilead

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 189

    2020 Revenue in Millions : 196

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ICMD China
    Not Confirmed

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    U.S.A
    arrow
    ICMD China
    Not Confirmed

    Johnson & Johnson

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 2,083

    2020 Revenue in Millions : 2,184

    Growth (%) : -5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Revenue share - Symtuza

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ICMD China
    Not Confirmed

    Brand Name : Revenue share - Symtuza

    U.S.A
    arrow
    ICMD China
    Not Confirmed

    Gilead

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2022 Revenue in Millions : 530

    2021 Revenue in Millions : 531

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Genvoya

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ICMD China
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    ICMD China
    Not Confirmed

    Gilead

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2022 Revenue in Millions : 2,404

    2021 Revenue in Millions : 2,879

    Growth (%) : -16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.